Grant of Options

RNS Number : 1454D

Epistem Holdings plc

25 March 2014

 



For Release           25 March 2014

Epistem Holdings Plc

("Epistem" or "the Company")

Grant of Options

Following the recommendation of the remuneration committee, the Company has today made the following option award to Allan Brown, the Chief Operating Officer of the CompanyÕs diagnostics division:

• options over 200,000 ordinary shares of 1.5p each, exercisable at 325p per share, being the closing  middle market price of EpistemÕs ordinary shares on 24 March 2014.  These options are exercisable from 25 March 2017 until 25 March 2024 in accordance with standard performance conditions.

For further information contact:

Epistem Plc

Matthew Walls, Chief Executive Officer                                                          [phone]                                  

John Rylands, Finance Director                                                       

Peel Hunt LLP 

James Steel                                                                                                [phone]   

Clare Terlouw                                                      

Wallbrook PR

Mike Wort

Anna Dunphy                                                                                                                                 [phone]

Notes for editors

Epistem is a biotechnology and personalised medicine company commercialising its expertise in stem cells in the areas of epithelial (oncology, gastrointestinal and dermatological) and infectious diseases. Epistem develops innovative therapeutics, biomarkers and diagnostics (Genedrive^¨)alongside contract research services for drug development companies. The GroupÕs core expertise is focused around the regulation of adult stem cells located in epithelial tissue including the gastrointestinal tract, skin, hair follicles, breast and prostate and utilizing novel, proprietary next generation molecular biology for use in personalised medicine. www.epistem.co.uk

 

END

 

 

MSCBSGDXSSDBGSU